Kornimate/medical-research-clean huggingface dataset:
correlation of spo2/fio2 ratio with pao2/fio2 ratio in ards patients in the icu of h. adam malik hospital

Conditions: Ards

Summary: this study to apprehend the relation of spo2/fio2 to pao2/fio2 in ards patients.

acute respiratory distress syndrome (ards) is a life-threatening condition that requires immediate treatment. the measurement of the pao2/fio2 (p/f) ratio is the main choice for assessing the severity of ards with an invasive method that requires arterial blood gas (abg) analysis. this study was conducted to determine the relationship between the spo2/fio2 ratio and the pao2/fio2 ratio in ards patients at ham general hospital. this observational study used a cross-sectional research method with the total sample of 29 intubated icu patients diagnosed with ards. patients with congestive heart failure, anemia, and systolic blood pressure \<90 mmhg were excluded from the study. the results of this study showed a positive correlation between the pao2/fio2 and spo2/fio2 ratios with a correlation coefficient of 0.955 and a p-value of 0.001. there was a relationship between the s/f ratio and the p/f ratio in assessing the severity of ards with a p-value of \<0.05. this study shows that the spo2/fio2 (s/f) ratio has a good correlation with the pao2/fio2 (p/f) ratio in patients with ards, so it can be used as a predictor of ards and can be beneficial in clinical practice. it should be noted that the spo2/fio2 ratio has several factors that can affect its accuracy, so careful assessment is needed.

Eligibility criteria:
inclusion criteria: * ards patient * intubarted patient exclusion criteria: * cardiac congenital disorder
ex-vivo reversion of platelet inhibition induced by prasugrel

Conditions: Acquired Platelet Disorder

Summary: the purpose of this ex-vivo study is to estimate the optimal platelet quantity necessary to reverse the antiplatelet effects of prasugrel.


Eligibility criteria:
inclusion criteria: * acute coronary syndrome * prasugrel loading dose 6-24h before inclusion exclusion criteria: * clopidogrel loading dose * gpiibiiia use within 10 days before inclusion * known congenital thrombopathy and/or congenital coagulation defect
effects of corticotropin releasing hormone (crh) on the sleep in patients with hypopituitarism

Conditions: Hypopituitarism

Summary: in contrast to healthy subjects, patients with hypopituitarism do not exhibit endocrine responses when hormones are injected. this is at least true for those with a complete insufficiency of the anterior pituitary. for example, administration of corticotropin releasing hormone (crh) is not followed by an increase of acth and cortisol. therefore, "pure" hormone effects can be investigated. it is well established that hormones of the hypothalamic-pituitary-adrenal axis are involved in sleep regulation. in rodents, crh decreased slow wave sleep (sws). in humans, crh was reported to increase wakefulness and to decrease sws and rem sleep. primary objective was therefore to study the effect of crh on patients with hypopituitarism. to date, there is no information on sleep of patients with hypopituitarism. secondary objective is therefore to compare sleep of patients with hypopituitarism with sleep of age-matched healthy controls.


Eligibility criteria:
patients with hypopituitarism inclusion criteria: * age 18-75 years * complete insufficiency of the anterior pituitary * stable hormone substitution for at least 3 months exclusion criteria: * hormone excess in the past * sleep disorder, e.g. sleep apnea syndrome healthy controls inclusion criteria: * age 18-75 years exclusion criteria: * any medication during 6 week prior to study entry * shift work

Keywords: patients with hypopituitarism
safety/efficacy of everolimus and neoral® in adult cardiac transplant patients with established allograft vasculopathy

Conditions: Graft Rejection

Summary: everolimus is an immunosuppressive drug that is being studied for preventing acute rejection that can happen after heart transplantation. it is usually used in combination with other immunosuppressive drugs such as cyclosporine. the purpose of this study is to evaluate the change in kidney function after beginning everolimus, while determining the most effective neoral® (cyclosporine) dose to take with everolimus, in adult cardiac transplant patients who have had their transplanted heart for at least 1 year and who have cardiac allograft vasculopathy.


Eligibility criteria:
inclusion criteria: * male or female adult with an established cardiac allograft vasculopathy defined as any new luminal irregularity on coronary angiography. * patient must be on statins at study entry. * patient who is more than 12 months post-transplant. exclusion criteria: * patient with a serum creatinine value \>2.0 mg/dl. * patient with a biopsy-proven acute rejection episode (\>= ishlt 3a) within 6 months prior to study entry. * patient who had received any investigational drug within 4 weeks prior to study entry.

Keywords: transplant, heart, adult, everolimus allograft rejection
bryostatin 1 in treating patients with metastatic kidney cancer

Conditions: Kidney Cancer

Summary: phase ii trial to study the effectiveness of bryostatin 1 in treating patients who have metastatic kidney cancer. drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.

objectives: i. determine the objective response rate to bryostatin 1 in patients with advanced renal cell carcinoma. ii. assess the toxicities of this treatment regimen in this patient population. iii. determine the time to disease progression in patients receiving this treatment regimen. iv. determine the overall survival of this patient population treated with this regimen. outline: patients receive bryostatin 1 iv over 1 hour on days 1, 8, and 15. treatment continues every 4 weeks in the absence of unacceptable toxicity or disease progresssion. patients are followed every 3 months for 2 years, every 6 months for 3 years, and then annually thereafter.

Eligibility criteria:
disease characteristics: * histologically confirmed metastatic renal cell carcinoma * bidimensionally measurable disease * clear evidence of progression if only site of measurable disease is within previous radiation port * previously irradiated brain metastases allowed, if not life threatening, symptoms controlled for 3 months, and not requiring corticosteroids patient characteristics: * age: 18 and over * performance status: ecog 0-1 * life expectancy: greater than 3 months * wbc at least 3,000/mm3 * platelet count at least 100,00/mm3 * bilirubin no greater than 1.5 mg/dl * creatinine no greater than 2.0 mg/dl or creatinine clearance greater than 50 ml/min * not pregnant or nursing * negative pregnancy test * fertile patients must use effective contraception for 1 month before, during, and for 3 months after study * no active bacterial or viral infection * no serious underlying medical condition that would interfere with compliance * no other malignancy within the past 5 years except basal cell carcinoma of the skin * no dementia or altered mental status that would prevent informed consent prior concurrent therapy: * no more than 1 prior therapy with biologic response modifiers * no prior chemotherapy for advanced disease * no other concurrent chemotherapy * no concurrent steriods (except topical use) * at least 4 weeks since prior radiotherapy * no concurrent radiotherapy * at least 4 weeks since major surgery (including nephrectomy) * no other concurrent experimental agents

Keywords: stage iv renal cell cancer recurrent renal cell cancer
expanded access study of palbociclib (pd-0332991) in combination with letrozole as treatment of post-menopausal women with hr-positive, her2-negative advanced breast cancer for whom letrozole therapy is deemed appropriate

Conditions: Advanced Breast Cancer (Female)

Summary: to provide access to palbociclib to post-menopausal women with hr-positive, her2-negative advanced breast cancer who are deemed appropriate for letrozole therapy (canada: first-line patients only).

this study is currently available in canada only.

Eligibility criteria:
inclusion criteria: * post-menopausal women 18 years of age or above with proven diagnosis of advanced adenocarcinoma of the breast (locoregionally recurrent or metastatic disease) * er-positive and/or pr-positive tumor based on local laboratory results * her2-negative tumor based on local laboratory results * patients must be appropriate candidates for letrozole therapy (canada: first-line patients only) exclusion criteria: * patients who have previously participated in a palbociclib trial or who have received prior treatment with any cdk inhibitor

Keywords: expanded access advanced breast cancer
inhibition of sterile inflammation by digoxin

Conditions: Inflammatory Response

Summary: to investigate the effect of digoxin on pyruvate kinase isoform 2 (pkm2) binding to pro-inflammatory loci and innate immune inflammatory responses in the peripheral blood in healthy subjects.

to investigate the effect of orally administered digoxin on innate immune inflammatory responses in the peripheral blood of healthy subjects. we hypothesize the reduction in innate immune inflammatory responses will be expected in the peripheral blood with the effect of oral digoxin. to investigation how human peripheral blood immune cells change their inflammatory responses after exposure to digoxin in vitro.

Eligibility criteria:
inclusion criteria 1. age \>18 y ≤ 70 years 2. subjects with normal serum creatinine, normal ekg and currently not taking any medication. exclusion criteria 1. autoimmune liver disease (ana \> 1/320) 2. chronic viral hepatitis 3. hepatocellular carcinoma 4. complete portal vein thrombosis 5. extrahepatic terminal disease 6. pregnancy 7. treatment with prednisolone or pentoxifyllin for more than 3 days prior to inclusion/start date 8. active alcohol abuse (\>50 g/day for men and \>40 g/day for women) in the last 3 months 9. ast \> alt and total bilirubin \> 3 mg/dl in the past 3 months 10. liver biopsy and/or clinical picture consistent with alcoholic hepatitis 11. lack of signed informed consent. 12. known hypersensitivity to digoxin or other forms of digitalis, ventricular fibrillation. 13. any significant medical conditions, any electrolyte abnormalities, over the counter medications, natural products and prescription drugs.
iris-premier registry

Conditions: Coronary Artery Disease; Myocardial Ischemia; Coronary Disease; Heart Diseases

Summary: the purpose of this study is to evaluate effectiveness and safety of promus premier in routine clinical practice


Eligibility criteria:
inclusion criteria: * age 20 and more * intervention with promus premier everolimus eluting coronary stent * agreed with written informed consent form exclusion criteria: * intervention with promus premier everolimus eluting coronary stent and other drug eluting stent at the same time * life expectancy of 1year and under * cardiac shock

Keywords: promus premier routine clinical practice
traumatic brain injury positive strategies

Conditions: Brain Injuries, Traumatic

Summary: this study evaluates the effectiveness of the traumatic brain injury positive strategies (tips) program, a comprehensive educational and training resource to help families improve their knowledge and skills in supporting a child with tbi experiencing cognitive, behavioral, and social challenges. the application provides training in evidence-based support strategies with the goal of improving outcomes for children with tbi and their families. half the participants will receive access to the tips program, while the other half will receive access to a different tbi related website.

due to the chronic nature of cognitive and behavioral problems related to tbi, parents and other family caregivers need information, resources, and training in evidence-based strategies to manage the varied and changing concerns following their child's injury. recent research provides evidence that theory-driven, self-directed online parent training is effective in improving both child and parent outcomes. the objective of this project is to produce the traumatic brain injury positive strategies (tips) program, a comprehensive educational and training resource to help families improve their knowledge and skills to address cognitive, behavioral, and social challenges following pediatric tbi. the tips program will be grounded in the theory of planned behavior, which postulates that training in problem-solving leads to improved skills and increases in perceived behavioral control that mediate direct changes in parenting behaviors and indirect changes in child outcomes. the web-based product will include: (a) the training center, which will provide training in a range of evidence-based strategies within a problem-solving framework; and (b) the tbi resource center, an extensive library of educational materials, information, and resources about childhood tbi. approximately 216 family members will participate in the evaluation phase of this study. participants will be randomly assigned to one of two conditions: (a) treatment (tips program ) or (b) control (brain injury website).

Eligibility criteria:
inclusion criteria: * adult 18 years old or older * have a child age 3-18 that was hospitalized overnight with a traumatic brain injury (tbi). * involved in the care and support of the child with the tbi. * live in the same household as child with a tbi. * the child with the tbi is able to follow simple instructions such as "please eat your toast." exclusion criteria: * does not speak and read english. * does not have high speed internet access. * not us resident
managing dentine hypersensitivity with silver diamine fluoride on older adults

Conditions: Dentine Hypersensitivity

Summary: background: dentine hypersensitivity is a common oral complaint from older adults. it induces pain, affects oral hygiene practice, limits food choices and negatively affects the quality of life. silver diamine fluoride (sdf) is a desensitizing agent but well-designed clinical trials are lacking. the objective of this study is to evaluate the effectiveness of sdf in reducing dentine hypersensitivity in older chinese adults. methods: this is a double-blinded randomised clinical trial recruiting 166 healthy older adults aged 65 or over after having written consent. a trained calibrated examiner will conduct clinical examination and assess dentine hypersensitive using a blast of compressed air delivered from 3-in-1 syringe. older adults with a tooth with a self-perceived sensitivity score (ss) of 8 or above will be recruited. they will then be block randomised to receive either 38% sdf solution or 5% potassium nitrate every 4 weeks on the exposed root surface of the most hypersensitive tooth. the visible plaque index, bleeding on probing and probing depth (mm) will be recorded on the most hypersensitive tooth. the same examiner will perform clinical examination and assess the dentine hypersensitivity using the same tools and methods at 4-week and 8-week follow-ups. the examiner and older adults will be blinded to treatment allocation. the primary outcome is the percentage of change in ss before and after intervention at 8 weeks. the secondary outcome will be the percentage of change in vpi before and after intervention at 8 weeks. clinical significance: it will provide evidence to manage dentine hypersensitivity in older adults in clinical care.


Eligibility criteria:
inclusion criteria: * generally healthy; * no known or suspected allergy to the study ingredients or materials * have all active dental diseases under control but reported hypersensitivity exclusion criteria: * using any desensitizing agent within one month * have major systemic diseases such as cancer * receive medications that may affect pain perception within one month * have dentine hypersensitivity due to other dental conditions such as caries * are not able to give written consent
growing healthy hearts: a pilot randomized control trial to test gardening as an intervention to improve health

Conditions: Cardiovascular Diseases

Summary: the purpose of this study is to test the effect of group-based nutrition advice plus gardening (intervention) versus group-based nutrition advice alone on dietary intake of fruits and vegetables, physical activity, and lifetime risk for cardiovascular disease (cvd).

study participants will be randomly assigned to attend group sessions related to gardening with nutrition advice or nutrition advice alone. the main goal of the intervention will be to encourage participants to increase their intake of fruits and vegetables.

Eligibility criteria:
inclusion criteria: 1. are at least 20 years old 2. have transportation and are willing to travel to the hershey community garden 3. have any two health conditions or risk factors for cvd. these include, but are not limited to: 1. any history of cardiovascular disease 2. any family history of premature cardiovascular disease 3. any history of stroke 4. high cholesterol 5. high blood pressure 6. overweight/obesity (bmi \>=25) 7. diabetes 8. current or past tobacco use exclusion criteria: 1. currently tends a vegetable garden 2. moving out of the area in the next 4 months 3. non-english speaking 4. pregnant women 5. participation in a past gardening study 6. medical conditions or medications that limit ability to freely increase dietary intake of fruits and vegetables (e.g., kidney failure, dialysis) 7. a medical condition that precludes safe pursuit of gardening, i.e., recent heart conditions (e.g., heart failure, stroke, heart attack), recent or pending surgery, severe orthopedic conditions, pending hip/knee replacement, paralysis, dementia, blindness, unstable angina or uncontrolled arrhythmias, or uncontrolled asthma or allergies. 8. history of difficulty obtaining blood samples or fear of needles

Keywords: cardiovascular disease
team clinic: virtual expansion of an innovative multi-disciplinary care model for adolescents and young adults with type 1 diabetes

Conditions: Type 1 Diabetes

Summary: team clinic is a new care approach for middle and high school aged patients living with t1d and their families. this study is a 15-month randomized control trial (rct) that consists of virtual team clinic care appointments (primarily telemedicine, and in-person as necessary) and virtual team clinic group appointments with a multidisciplinary diabetes care team. assignment into 1 of 4 intervention groups team clinic care vs. standard care which consist of either virtual team clinic group or no group. groups: 1. standard care - no group 2. standard care - virtual team clinic group 3. team clinic care - no group 4. team clinic care - virtual team clinic group virtual team clinic group sessions will be facilitated by clinical care team (e.g., registered dietician, social worker, registered nurse, etc.) * patients and parents will attend their own online session

team clinic is an innovative approach to addressing patient developmental, psycho-social, and familial challenges; while also tackling the medical infrastructure and multi-disciplinary care challenges encountered by middle school and high school aged individuals with type 1 diabetes and their caregivers. this new approach consists of team clinic care appointments (primarily telemedicine, and in-person as necessary). the study incorporates virtual team clinic group/medical group appointments with a multidisciplinary diabetes care team of diabetes care providers. each group will have a special theme (thematic group visits) and learning experience aimed at improving glycemic control and treatment adherence, increasing social supports and diabetes care satisfaction, and aid in the transition from caregiver led treatment to self care. part of the goal of vtc is to spend less time in clinic while still receiving important diabetes education, support, and medical care.

Eligibility criteria:
inclusion 1. diagnosis of type 1 diabetes \> 6 month duration 2. grades 6th, 7th, and 8th ,9th, 10th, 11th, 12th at time of intervention 3. not currently participating in other group interventions 4. english speaking exclusions 1. severe behavioral or developmental disabilities in parent or child 2. severe psychological diagnoses in parent or child that would make group participation difficult 3. significant comorbid medical conditions that would make the patient non-eligible for group participation (e.g. cystic fibrosis, uncontrolled thyroid disease) 4. non-english speaking

Keywords: adolescents young adults group medical visits
a dose-ranging study evaluating the safety and efficacy of idp-108 in patients with onychomycosis

Conditions: Onychomycosis

Summary: the purpose of this study is to assess the safety and effectiveness of two concentrations of idp-108 in treating patients with onychomycosis


Eligibility criteria:
inclusion criteria: * presence of onychomycosis of the target toenail * a positive fungal culture from the target toenail exclusion criteria: * any disease or condition that might cause nail abnormalities or may interfere with clinical evaluations * presence of tinea pedis (athletes foot) * female subjects who are pregnant, nursing, planning a pregnancy, or become pregnant during the study
neurophysiological characterization of postherniotomy pain

Conditions: Postoperative Pain; Postherniotomy Pain; Neuropathic Pain

Summary: sensory function is different in persistent postherniotomy pain patients than in operated controls, suggesting this to be a neuropathic pain syndrome. by performing quantitative sensory testing, the specific changes in pain patients will be revealed, thereby aiding in designing future treatment trials. mri scans of the groin regions in pain patients and control patients will be evaluated by senior mri specialists assessing potential pathology to the region (mesh, inflammation, edema, funicle etc.) assessors will be blinded to clinical status, and surgery.


Eligibility criteria:
inclusion criteria: * male patients \>18 yrs * inguinal herniotomy \>1 yr previously * no sign of hernia recurrence * unilateral chronic groin pain lasting more than 3 months * moderate/severe pain related impairment of everyday activities. exclusion criteria: * other causes of persistent pain in groin region (hip, other surgical procedures)

Keywords: groin hernia pain chronic quantitative sensory testing persistent postoperative pain